Significance of soluble sera apoptosis inhibitive factor sFas in patients with Graves disease

Abstract

Objective To explore the function of soluble apoptosis inhibitive factor Fas (sFas) in pathogenesis of Graves ophthalmopathy (GO). Methods The subjects were enrolled in the Second Affiliated Hospital of Harbin Medical University from January 2014 to January 2017, and they were divided into three groups: GO accompanied with Graves disease (GD) group, GO without GD group and normal control group, with 30 patients in each group. Serum levels of sFas in three groups were investigated with enzyme-linked immunosorbent assay, and serum levels of freeing triiodothyronine (FT3), serum free thyroxine (FT4), thyrotrophin (TSH), thyroglobulin antibody (TGAb), thyroid peroxidase antibody (TPOAb) were measured by chemoluminescent technique, and compared. Results The serum level of sFas in GO accompanied with GD group was (0.76 ± 0.13) µg/L, which was higher than that in GO without GD group [(0.63 ± 0.08) µg/L] and normal control group [(0.52 ± 0.05) µg/L], and there was significant difference (P 0.05). Conclusions Abnormal serum concentration of sFas can be observed in patients with GD and GO which proves that sFas may play a role in the pathogenesis of GD and GO. Key words: Graves ophthalmopathy; Apoptosis; Soluble Fas